Clinicopathological Characteristics and Outcomes of Adult Patients with Idiopathic Membranoproliferative Glomerulonephritis According To an Immunofluorescence-based Classification

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2024 Oct 14

PMID 39400860

Authors

Tabassum Elahi

Saima Ahmed

Ejaz Ahmed

Muhammed Mubarak

Affiliations

Soon will be listed here.

Abstract

Background: The classification of membranoproliferative glomerulonephritis (MPGN) into immune complex-mediated MPGN and complement-mediated MPGN on immunofluorescence has provided insights into two distinct disease processes. There are limited data available on renal outcomes of MPGN from developing countries.

Methods: A retrospective analysis was conducted on biopsy-proven MPGN cases diagnosed between 1998 and 2018 at the Sindh Institute of Urology and Transplantation (SIUT). Secondary causes were excluded. Patients were reclassified as immune complex-mediated-MPGN and complement-mediated-MPGN based on immunofluorescence results. The clinicopathological findings and outcomes of the two groups were compared.

Results: In total, 213 patients with idiopathic MPGN were identified. Among these, 163 (76.5%) were reclassified as immune complex-mediated-MPGN and 50 (23.4%) as complement-mediated-MPGN. No significant differences were found between the two groups regarding age, gender, clinical characteristics, biopsy indications, biopsy findings, and renal function at presentation. Overall, 63 subjects (38.7%) with immune complex-mediated-MPGN and 27 (54%) with complement-mediated-MPGN received immunosuppressive agents (p = 0.08). Complete and partial remission rates were higher in immune complex-mediated-MPGN than in complement-mediated-MPGN (76% vs 58%, p < 0.05). At two years, median estimated glomerualr filtration rate (eGFR) tended to be higher in patients with immune complex-mediated-MPGN 91.2 (45.4-113.7) vs 83.45(34.6-102.50) ml/min/1.73 m, p = 0.22) with significantly better renal survival (76% vs 58%, p = 0.03). Comparatively, more patients progressed to end-stage kidney disease (ESKD) in the complement-mediated-MPGN group (32% vs 19.6%, p = 0.06), with increased overall mortality (5 (10%) vs 7 (4.3%), p = 0.12).

Conclusion: The clinicopathological features at presentation of complement-mediated-MPGN are similar to those of immune complex-mediated-MPGN. However, it is less frequent and overall prognosis is less favorable.

References

DAgati V, Bomback A . C3 glomerulopathy: what's in a name?. Kidney Int. 2012; 82(4):379-81. DOI: 10.1038/ki.2012.80. View

Fervenza F, Sethi S, Glassock R . Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrol Dial Transplant. 2012; 27(12):4288-94. DOI: 10.1093/ndt/gfs288. View

Chothia M, Panday A, Coetzee L, Bates W . Outcomes of immunoglobulin-associated mesangiocapillary glomerulonephritis: A South African experience. Nephrology (Carlton). 2020; 25(10):765-774. DOI: 10.1111/nep.13736. View

Orth S, Ritz E . The nephrotic syndrome. N Engl J Med. 1998; 338(17):1202-11. DOI: 10.1056/NEJM199804233381707. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y . Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children. Nephrology (Carlton). 2014; 20(4):286-92. DOI: 10.1111/nep.12382. View

Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M . Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol. 2016; 31(7):1091-9. DOI: 10.1007/s00467-015-3307-z. View

Holle J, Berenberg-Gossler L, Wu K, Beringer O, Kropp F, Muller D . Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Pediatr Nephrol. 2018; 33(12):2289-2298. DOI: 10.1007/s00467-018-4034-z. View

Khandelwal P, Bhardwaj S, Singh G, Sinha A, Hari P, Bagga A . Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. Pediatr Nephrol. 2020; 36(3):591-600. DOI: 10.1007/s00467-020-04736-8. View

10.

Kirpalani A, Jawa N, Smoyer W, Licht C . Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney Int Rep. 2020; 5(12):2313-2324. PMC: 7710848. DOI: 10.1016/j.ekir.2020.09.019. View

11.

Nakano M, Karasawa K, Moriyama T, Uchida K, Nitta K . Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Clin Exp Nephrol. 2019; 23(6):852-858. DOI: 10.1007/s10157-019-01716-7. View

12.

Nargund P, Kambham N, Mehta K, Lafayette R . Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Clin Nephrol. 2015; 84(6):323-30. DOI: 10.5414/CN108619. View

13.

Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I . Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One. 2021; 16(9):e0257397. PMC: 8439563. DOI: 10.1371/journal.pone.0257397. View

14.

Fakhouri F, le Quintrec M, Fremeaux-Bacchi V . Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney Int. 2020; 98(5):1135-1148. DOI: 10.1016/j.kint.2020.05.053. View

15.

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E . Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016; 71:131-142. DOI: 10.1016/j.molimm.2016.01.010. View

16.

Schmitt H, Bohle A, Reineke T, VOGL W . Long-term prognosis of membranoproliferative glomerulonephritis type I. Significance of clinical and morphological parameters: an investigation of 220 cases. Nephron. 1990; 55(3):242-50. DOI: 10.1159/000185969. View

17.

Chan M, Chan K, Chan P, Fang G, Cheng I . Adult-onset mesangiocapillary glomerulonephritis: a disease with a poor prognosis. Q J Med. 1989; 72(267):599-607. View

18.

Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H . Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2017; 22(4):797-807. DOI: 10.1007/s10157-017-1513-7. View

19.

Bomback A, Santoriello D, Avasare R, Regunathan-Shenk R, Canetta P, Ahn W . C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018; 93(4):977-985. DOI: 10.1016/j.kint.2017.10.022. View

20.

Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E . Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994; 67(1):59-65. DOI: 10.1159/000187889. View